America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What is the mechanism of action of the new cancer drug AOH1996 developed by Dr. Linda Malkas?
**Interview with Dr. Linda Malkas on the Development of a New Cancer Drug**
**Editor:** Welcome, Dr. Linda Malkas, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope Hospital. Thank you for joining us today to discuss this groundbreaking advancement in cancer treatment.
**Dr. Malkas:** Thank you for having me. It’s a pleasure to share our research with you.
**Editor:** Your team has recently developed a drug, AOH1996, which targets cancer cells in a novel way. Can you explain how this drug works?
**Dr. Malkas:** Certainly! AOH1996 is designed to target a specific variant of a protein called PCNA, which is crucial for DNA replication and tumor growth. Think of PCNA as a major airport hub where all planes, in this case, cancer cells, are managed. Our drug acts like a blizzard that effectively shuts down that hub, selectively disrupting the reproductive cycle of cancer cells while sparing healthy ones.
**Editor:** That’s a fascinating analogy! What types of cancers has this drug shown promise in treating?
**Dr. Malkas:** We have seen significant results in clinical research for various types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Our studies showed that AOH1996 selectively kills cancer cells across more than 70 different cancer cell lines.
**Editor:** The implications of this are tremendous. What are the next steps for AOH1996?
**Dr. Malkas:** The next crucial step is to conduct human clinical trials. We’ve proven the efficacy of AOH1996 in preclinical studies, and we are enthusiastic about translating these findings into clinical applications that could provide new treatment options for patients.
**Editor:** That’s exciting news! How long do you anticipate the trials will take, and what do you hope to learn from them?
**Dr. Malkas:** The timeline for clinical trials can vary, but we aim to start them within the next couple of years. Our primary goals are to confirm the drug’s safety and effectiveness in humans, understand the optimal dosing, and further investigate how AOH1996 interacts with different types of cancers.
**Editor:** Thank you, Dr. Malkas, for providing us with this insight into your important work. We look forward to hearing more about AOH1996 and its potential impact on cancer treatment.
**Dr. Malkas:** Thank you for the opportunity. We are hopeful that our research can make a significant difference in the fight against cancer.
